Cadence Capital Management’s Emergent Biosolutions EBS Stock Holding History

Cadence Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-19,347	Closed	-$544K	–	628
2016 Q2	$544K	Sell	19,347 -6,734	-26%	-$264K	0.04%	431
2016 Q1	$948K	Buy	26,081 +390	+2%	+$13.8K	0.07%	308
2015 Q4	$1.03M	Sell	25,691 -11,907	-32%	-$415K	0.07%	278
2015 Q3	$1.07M	Sell	37,598 -11,072	-23%	-$365K	0.08%	280
2015 Q2	$1.6M	Buy	48,670 +10,500	+28%	+$326K	0.09%	282
2015 Q1	$1.1M	Buy	38,170 +360	+1%	+$10.3K	0.07%	389
2014 Q4	$1.03M	Sell	37,810 -38,577	-51%	-$919K	0.06%	395
2014 Q3	$1.63M	Sell	76,387 -106,980	-58%	-$2.45M	0.09%	281
2014 Q2	$4.12M	Buy	+183,367	New	+$4.27M	0.2%	201

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadence Capital Management's EBS Position: Q3 2016 in Review

Cadence Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2016, closing a stake of 19,347 shares — an estimated $544K sold.

Cadence Capital Management first reported a position in EBS in Q2 2014 and held it in 9 quarters. The position peaked at $4.12M in Q2 2014. 203 funds tracked by Wall St. Rank hold EBS as of Q3 2016.

Cadence Capital Management reported no remaining Emergent Biosolutions position as of Q3 2016 after selling out during the quarter.
Cadence Capital Management sold 19,347 Emergent Biosolutions shares in Q3 2016, an estimated $544K.
Cadence Capital Management first reported a position in Emergent Biosolutions in Q2 2014 and held it in 9 quarters.
Cadence Capital Management's Emergent Biosolutions position peaked at $4.12M in Q2 2014.
203 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2016.

Based on Cadence Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.